Angiotensin III (human, mouse): Atomic Insights for RAAS and Cardiovascular Research

Executive Summary: Angiotensin III (human, mouse) is a biologically active hexapeptide derived from angiotensin II by N-terminal cleavage via angiotensinase activity in erythrocytes and tissues (Oliveira et al., 2025). It mediates about 40% of the pressor activity of angiotensin II and fully stimulates aldosterone secretion, acting via AT1 and AT2 receptors with a preference for AT2 (Oliveira et al., 2025). The peptide is highly soluble in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), and DMSO (≥93.1 mg/mL), making it suitable for diverse experimental workflows (APExBIO). Angiotensin III is a valuable tool for dissecting renin-angiotensin-aldosterone system (RAAS) signaling, modeling hypertension, and studying neuroendocrine responses (see other RAAS workflows). Recent evidence connects its use to research on viral pathogenesis, including COVID-19 (Oliveira et al., 2025).

Biological Rationale

Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) is an endogenous peptide generated by enzymatic cleavage of angiotensin II, specifically via aminopeptidase A activity in blood and tissue compartments (Oliveira et al., 2025). As a core component of the renin-angiotensin-aldosterone system (RAAS), it regulates vascular tone, blood pressure, and aldosterone secretion. Angiotensin III is present in both human and mouse models, supporting translational research across species. Its biological effects are mediated by interaction with G protein-coupled receptors (GPCRs), especially the AT1 and AT2 receptor subtypes, both of which are distributed in cardiovascular, renal, and central nervous system tissues. Unlike angiotensin II, which is the primary effector of the RAAS, angiotensin III retains full aldosterone-stimulating potency and a substantial fraction of pressor activity, making it essential for mapping the redundancy and specialization of RAAS effectors (see comparative analysis).

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III is produced by the N-terminal cleavage of angiotensin II by angiotensinase enzymes. This process removes the aspartic acid residue, yielding the Arg-Val-Tyr-Ile-His-Pro-Phe sequence (CAS: 13602-53-4, APExBIO). Angiotensin III binds to both AT1 and AT2 receptors. While it activates AT1-mediated vasoconstriction and aldosterone release, it shows relative specificity and higher affinity for AT2, which is implicated in vasodilation and anti-fibrotic effects. In ex vivo and in vivo models, administration of angiotensin III induces aldosterone secretion from adrenal cortex cells and suppresses renin release, mimicking angiotensin II in these pathways (Oliveira et al., 2025). In rodent brains, angiotensin III elicits both pressor and dipsogenic (thirst-promoting) responses, highlighting its neuroendocrine roles. The peptide’s molecular formula is C₄₆H₆₆N₁₂O₉, and its molecular weight is 931.09 g/mol (APExBIO).

Evidence & Benchmarks

• Angiotensin III mediates approximately 40% of the vasopressor effect of angiotensin II, as quantified in rodent models (Oliveira et al., 2025).
• Experimental administration of angiotensin III fully stimulates aldosterone secretion in adrenal cortex assays (Oliveira et al., 2025).
• Angiotensin III binds and activates both AT1 and AT2 receptor subtypes, with relative specificity for AT2 observed in competitive binding studies (Oliveira et al., 2025).
• Exogenous angiotensin III induces dipsogenic and pressor responses in rodent brain microinjection models (internal article).
• Angiotensin III and related peptides can modulate the interaction between SARS-CoV-2 spike protein and AXL receptor, suggesting a role in COVID-19 pathogenesis (Oliveira et al., 2025).
• Optimal solubility parameters: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, ≥93.1 mg/mL in DMSO; stability is maximized when stored desiccated at -20°C (APExBIO).

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is widely used in cardiovascular disease models, neuroendocrine signaling studies, and for dissecting AT1/AT2 receptor signaling pathways. Its full aldosterone-stimulating ability makes it indispensable for experiments where delineating mineralocorticoid effects is critical. The peptide’s solubility and stability profile enable its integration into diverse in vitro and in vivo platforms, including perfused organ baths, cell signaling assays, and microinjection protocols (scenario-based guidance; this article updates those laboratory recommendations with recent COVID-19 bench findings). Recent literature highlights its role in viral pathogenesis studies, given RAAS interactions with SARS-CoV-2 spike protein binding (Oliveira et al., 2025). However, angiotensin III is not a universal RAAS surrogate; its receptor specificity, pressor efficiency, and metabolic stability differ from angiotensin II and other analogs, requiring careful control selection.

Common Pitfalls or Misconceptions

• Misconception: Angiotensin III is functionally identical to angiotensin II.
  Clarification: It mediates only ~40% of the pressor effect but retains full aldosterone-inducing capacity (Oliveira et al., 2025).
• Pitfall: Assuming cross-species effects without validation.
  Recommendation: Always verify receptor subtype expression and downstream pathways in both human and mouse models.
• Misconception: Long-term storage in solution is acceptable.
  Correction: Peptide should be stored desiccated at -20°C; long-term solution storage leads to degradation (APExBIO).
• Pitfall: Using angiotensin III to fully substitute for angiotensin IV in spike protein interaction studies.
  Note: Angiotensin IV may exhibit stronger enhancement of spike–AXL binding compared to angiotensin III (Oliveira et al., 2025).
• Misconception: All RAAS peptides display equal stability in organic solvents.
  Fact: Solubility and stability parameters are peptide-specific and must be experimentally confirmed (APExBIO).

Workflow Integration & Parameters

For precise experimental outcomes, angiotensin III (human, mouse) should be reconstituted according to its documented solubility: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO (APExBIO). Use freshly prepared solutions for each experiment, as storage in aqueous or organic solutions reduces peptide integrity. The molecular weight (931.09 g/mol) ensures accurate dosing for both in vitro and in vivo applications. For neuroendocrine studies, microinjection into rodent brain regions is validated for eliciting dipsogenic and pressor endpoints. In cell-based assays, titrate concentration to match receptor density and assay sensitivity, as overexposure may mask physiological signaling nuances. The A1043 kit from APExBIO provides validated purity and batch-to-batch consistency for reproducible results. For further protocol optimization, see our scenario-based recommendations; this article extends those by integrating recent viral pathogenesis applications.

Conclusion & Outlook

Angiotensin III (human, mouse) is an essential RAAS peptide for modern cardiovascular and neuroendocrine research. Its dual receptor activity, robust aldosterone induction, and translational relevance make it a preferred reagent for dissecting RAAS mechanism and pathology. Recent evidence linking angiotensin III and related peptides to SARS-CoV-2 spike protein interactions broadens its utility to infectious disease models. APExBIO’s A1043 product ensures standardized quality, supporting reproducible and high-impact research. For advanced experimental workflows and troubleshooting, see comparative analyses such as this RAAS-focused article—while that piece unpacks advanced protocol nuances, the current article updates mechanistic insights and viral applications. Future directions include leveraging angiotensin III as a therapeutic probe and biomarker in hypertension, heart failure, and emerging viral diseases.